CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Celcuity Inc. (CELC) (CELC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Celcuity Inc. (CELC) (CELC)

Services-Medical Laboratories · market cap $4.0B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-06-25
NDA Filing
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Celcuity (CELC) is a clinical-stage oncology company with a ~$3.22B market cap (~48.9M shares at ~$65.8). Its lead asset is gedatolisib in combination with palbociclib and fulvestrant (and a letrozole variant) in Phase 3 breast cancer, with additional entries in prostate (mCRPC), endometrial and triple-negative breast cancer. Our calendar shows only an estimated earnings date on 2026-11-11 as the next catalyst.
The catalyst path
  • 2027-06-25NDA Filingimp 6/10
  • 2027-06-25PDUFA · Gedatolisibimp 8/10
Pipeline
AssetPhaseIndication
GedatolisibPhase 3mCRPC (Metastatic Castration-resistant Prostate Cancer)
TalazoparibPhase 2TNBC - Triple-Negative Breast Cancer
LY3023414Phase 2Endometrial Cancer
Ribociclib + FulvestrantPhase 3Breast Cancer
Gedatolisib + Palbociclib + LetrozolePhase 3Breast Cancer
Gedatolisib + Palbociclib + FulvestrantPhase 3Breast Cancer
Price & technical context
3-month
-30.4%
6-month
-53.2%
12-month
-24.4%
52-wk range
$56.58–$144.98
vs 50-day MA
-11.2%
vs 200-day MA
-34.6%
Realized vol
65.4%
Max drawdown
-61.0%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for CELC (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.